鼻咽癌质子与光子放疗的听力保护比较
该前瞻性匹配队列研究纳入180例初治鼻咽癌患者,1:1匹配后分别接受调强质子治疗(IMPT)或容积旋转调强放疗(VMAT)。IMPT组耳蜗平均剂量显著更低,且听力结局(纯音听阈、高频听力、气骨导差、言语识别率)均优于VMAT组,提示IMPT可能减轻耳毒性。
要点
- IMPT组同侧和对侧耳蜗平均剂量均显著低于VMAT组。
- IMPT组平均纯音听阈和高频听力均优于VMAT组。
- IMPT组气骨导差更小、言语识别率更高、骨导损失更少。
核心结论
- IMPT较VMAT降低耳蜗剂量,带来更好的听力保护,可能减少鼻咽癌患者耳毒性。
研究设计与样本
- 前瞻性匹配队列研究,纳入2023至2025年180例初治鼻咽癌患者,按性别、年龄和疾病分期1:1匹配为IMPT组(n=90)和VMAT组(n=90)。
主要发现
- IMPT组同侧耳蜗平均剂量为47.51 Gy,VMAT组为56.82 Gy(P < .001;95% CI: -14.27至-4.35)。
- IMPT组对侧耳蜗平均剂量为30.79 Gy,VMAT组为45.71 Gy(P < .001;95% CI: -18.93至-10.91)。
- 基于最近一次听力评估(中位随访12.1个月,范围7.5-19.5个月),IMPT组平均纯音听阈为33.72 dB,VMAT组为42.00 dB(P = .016;95% CI: -14.91至-1.65)。
- IMPT组2至8 kHz高频听力为37.94 dB,VMAT组为53.82 dB(P < .001;95% CI: -23.69至-8.07)。
- IMPT组气骨导差为5.67 dB,VMAT组为10.62 dB(P < .001;95% CI: -6.80至-3.10);言语识别率分别为96.67%和94.00%(P = .039;95% CI: 0.14-5.20),且1至4 kHz骨导损失更少。
临床怎么用
- 对于需要根治性放疗的鼻咽癌患者,选择IMPT可能有助于降低耳蜗剂量并保护听力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare cochlear dose and hearing outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) in patients with nasopharyngeal carcinoma (NPC). STUDY DESIGN: Prospective matched cohorts. SETTING: Tertiary academic center. METHODS: A total of 180 newly diagnosed, treatment-naive NPC patients receiving definitive radiotherapy between 2023 and 2025 were enrolled. Patients were 1:1 matched by sex, age, and disease stage, and assigned to IMPT (n = 90) or VMAT (n = 90). Mean cochlear dose was recorded. Audiological evaluations, including pure-tone audiometry (PTA), air-bone gap, and word recognition score, were performed before and after treatment. RESULTS: IMPT delivered significantly lower mean doses to the ipsilateral (47.51 vs 56.82 Gy, P < .001; 95% CI: -14.27 to -4.35) and contralateral cochlea (30.79 vs 45.71 Gy, P < .001; 95% CI: -18.93 to -10.91). Based on each patient's most recent audiometric assessment (median follow-up, 12.1 months; range, 7.5-19.5 months), IMPT demonstrated better average PTA thresholds than VMAT (33.72 vs 42.00 dB; P = .016; 95% CI, -14.91 to -1.65), superior high-frequency hearing at 2 to 8 kHz (37.94 vs 53.82 dB; P < .001; 95% CI, -23.69 to -8.07), lower air-bone gap (5.67 vs 10.62 dB; P < .001; 95% CI, -6.80 to -3.10), and higher word recognition scores (96.67% vs 94.00%; P = .039; 95% CI, 0.14-5.20), with less bone conduction loss at 1 to 4 kHz. CONCLUSION: IMPT reduces cochlear dose compared to VMAT, resulting in better hearing preservation and suggesting its potential to minimize ototoxicity in NPC patients.
引用
- Lien KH, Lin CY, Chen PY, et al. Auditory Preservation in Nasopharyngeal Carcinoma: Comparison of Proton and Photon Radiotherapy. Otolaryngol Head Neck Surg. 2026. PMID: 41503873. doi:10.1002/ohn.70113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。